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Abstract
Background: There are marked ethnic differences in the susceptibility to the long-term diabetic vascular complications
including sensory neuropathy. The vascular endothelial growth factor (VEGF) +405 (C/G) and −460 (T/C) polymorphisms
are associated with retinopathy and possibly with nephropathy, however no information is available on their relationship
with peripheral neuropathy. Therefore, we examined the prevalence of these VEGF genotypes in a multi-ethnic cohort of
patients with diabetes and their relationship with evident peripheral diabetic neuropathy.
Methods: In the current investigation, we studied 313 patients with diabetes mellitus of African-Caribbean, Indo-Asian
and Caucasian ethnic origin residing in an inner-city community in London, United Kingdom attending a single
secondary care centre. Genotyping was performed for the VEGF +405 and VEGF −460 polymorphisms using a
pyrosequencing technique.
Results: Forty-nine patients (15.6%) had clinical evidence of peripheral neuropathy. Compared to Caucasian patients,
African-Caribbean and Indo-Asian patients had lower incidence of neuropathy (24.6%, 14.28%, 6.7%, respectively; P = 0.04).
The frequency of the VEGF +405 GG genotype was more common in Indo-Asian patients compared to African-Caribbean
and Caucasian patients (67.5%, 45.3%, 38.4%, respectively; p ≤ 0.02). The G allele was more common in patients with type
2 diabetes of Indo-Asian origin compared to African-Caribbean and Caucasian origin (p ≤ 0.02). There was no difference
between the ethnic groups in VEGF −460 genotypes. The distributions of the VEGF +405 and VEGF −460 genotypes were
similar between the diabetic patients with and without neuropathy.
Conclusions: In this cohort of patients, VEGF +405 and VEGF −460 polymorphisms were not associated with evident
diabetic peripheral neuropathy, however an association was found between VEGF +405 genotypes and Indo-Asian which
might have relevance to their lower rates of ulceration and amputation. This finding highlights the need for further
investigation of any possible relationship between VEGF genotype, circulating VEGF concentrations and differential
vulnerability to peripheral neuropathy amongst diabetic patients of different ethnic backgrounds.
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Background
Peripheral neuropathy affects up to 50% of patients with
diabetes [1]. It is a major risk factor that makes diabetes
responsible for 50–75% of non-traumatic amputations in
the world [2, 3]. The pathogenesis of diabetic neuropathy
is poorly understood, but is likely to be multifactorial, a re-
sult of genetic susceptibility, environmental and lifestyle
factors [4, 5].
There is increasing evidence that the prevalence of
peripheral neuropathy as a complication of diabetes var-
ies according to race/ethnicity. The North American and
European studies of multi-ethnic groups have found a
greater prevalence of neuropathy occurring in Caucasian
patients compared to other ethnic groups [6]. Population
based studies in the United Kingdom (UK) have reported
lower rates of peripheral neuropathy in patients with type
2 diabetes of Indo-Asian and African-Caribbean origin
compared with those of Caucasian origin [7–9]. Studies
showing evidence of increased skin microvascularization
in Indo-Asian subjects has been considered a cause for the
lower rates of neuropathy compared with Caucasian sub-
jects [10]. These findings were independent of glycaemic
control and traditional risk factors for vascular disease,
suggesting that genetic, or some other, as yet unidentified
protective factor(s) may be relevant to these observations.
Strict metabolic control of hyperglycaemia is essential
in preventing the onset and progression of diabetic neur-
opathy [2, 3]. Hyperglycaemia disrupts sensory nerve
function through several mechanisms including, local
hypoxia, activation of protein kinase C, formation of
advanced glycation end products, oxidative stress and
pro-inflammatory changes [4, 5]. A counter-response to
these metabolic perturbations is the stimulation of gene
expression of the angiogenic cytokine, Vascular Endothe-
lial Growth Factor (VEGF) which attempts to alleviate
hypoxia and improve nutrient supply.
A positive correlation has been reported between stim-
ulated peripheral blood mononuclear cell VEGF protein
production and the +405 GC VEGF gene polymorphism
[11]. The highest VEGF protein production was noted
in individuals who were +405 GG homozygous, while
the lowest production was seen in subjects who were
+405CC. In patients with diabetes, several authors have
shown associations between the VEGF +405 and VEGF
−460 genotypes with microvascular and macrovascular
complications [12–16]. However, no study has yet in-
vestigated the relationship of these polymorphisms and
the vulnerability to diabetic neuropathy.
Therefore, the aim of this study is to determine the
distribution of VEGF +405 and VEGF −460 gene (Gene-
bank numbers rs2010963 and rs833061) polymorphisms
in Indo-Asian, African-Caribbean, and Caucasian patients
with diabetes and examine the relationship with clinical
evidence of diabetic peripheral neuropathy.
Methods
Patients
The study was conducted at a secondary care centre in
North London, UK, serving an inner-city community of
154,000 adults. Consecutive adult, attendees to the dia-
betes unit of Caucasian, Indo-Asian or African-Caribbean
ethnicity were invited to take part in the study. Patients
were considered to be of African-Caribbean or Indo-Asian
ethnicity if both parents were native to either African or
Caribbean countries or India, Pakistan, Bangladesh or Sri
Lanka respectively. The parents of white, Caucasian pa-
tients were native of Western European or Mediterranean
countries. A diagnosis of type 2 diabetes was based on an
absence of ketosis or need of insulin within 1 year of diag-
nosis. Type 1 diabetes was confirmed in each subject on
the basis of the diagnosis being made at less than 35 years
of age with a history of ketosis at presentation and
continuous use of subcutaneous insulin within 1 year
from diagnosis. Patients with history of malignancy were
excluded.
Patients were diagnosed as having peripheral sensory
neuropathy if they had diminished sensation to light touch
with the 10 g monofilament or to pinprick. Body mass
index (BMI) was calculated from weight in kilograms di-
vided by height in meters squared. Sitting blood pressure
was measured after 10 min rest using a validated auto-
mated machine (OMRON 705HEM CP; OMRON Health-
care, West Sussex, U.K.) using an appropriate cuff size.
Fasting venous blood was taken from an antecubital
vein. Glycosylated Haemoglobin A1c (HbA1c) was mea-
sured by a high-performance liquid chromatography sys-
tem (Menarini 8140; Menarini Diagnostics, Wokingham,
U.K.). Total cholesterol, HDL cholesterol and total tri-
glycerides were estimated using enzymatic methods
(Boehringer-Mannheim, Mannheim, Germany). The
samples were coded in order to blind the laboratory
staff to the patients’ sex, age, racial origin, diabetes,
and comorbidity status.
The study was approved by the ethics committee of
the Whittington Hospital National Health Service Trust.
Written, informed consent was provided by all patients
entering the study.
DNA extraction
A modification of the method described by Miller et al.
[17] was used. Briefly, 1 mL of the blood collected in so-
dium citrate and stored at −80 °C was re-suspended in
2 mL of erythrocyte lysis solution (1.44 mM ammonium
chloride, 1 mM sodium bicarbonate) and the suspension
centrifuged at 15,000×g for 2 min. The supernatant was
discarded, and the pellet was re-suspended in 0.64 mL
nuclear lysis buffer [(10 mM Tris-HCl (pH = 8.2), 0.4 M
sodium chloride, 2 mM di-sodium EDTA (pH = 8.0)],
0.18 mL sodium chloride, and chloroform. The samples
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were shaken vigorously and centrifuged at 10, 000×g
for 3 min. The supernatant containing the DNA was
transferred into new eppendorf tubes and 1 mL of
100% ethanol was added and the tubes were inverted
repeatedly. The samples were centrifuged for 2 min at
10, 000×g. The supernatant was discarded and the pel-
let, containing DNA was dissolved in %70 ethanol and
the samples were centrifuged at 10, 000×g for 2 min.
The upper layer was then removed and polymerase
chain reaction (PCR) grade water was added. The con-
centration and purity of DNA was measured using a
NanoDrop spectrophotometer (NanoDrop Technologies,
Wilmington, DE).
Polymerase chain reaction
Polymerase chain reaction procedure was performed in
a total volume of 25 μL reaction mixture that contained
“Red Hot” Taq DNA polymerase enzyme (0.5 U), genomic
DNA (250 ng), 20 pmol of each primer set (sequences
shown in Table 1) and Mg2+ (1.5 mM).
All PCR mixes were amplified with the same touch
down program: Denature at 95 °C for 5 min followed by
35 cycles of [denaturation (95 °C for 1 min), annealing
(55 °C for 1 min) and extension (72 °C for 1 min)] and a
final step of extension at 72 °C for 10 min.
Pyrosequencing
PCR product (10 μL) was immobilised onto sepharose
streptavidin-coated beads (Amersham Bioscience, Amer-
sham, UK) suspended in binding buffer (10 mM Tris-HCl,
2 M NaCl, 1 mM EDTA, 0.1% Tween 20, pH 7.6) and
water to a total volume of 70 μL, at room temperature
(21 °C) for 5 min. Single-stranded (ss) DNA was obtained
by washing the immobilised PCR product for 5 s succes-
sively in 70% ethanol, 0.2 M NaOH and washing buffer
(10 mM Tris-acetate) followed by 12 μL annealing buffer
(20 mM Tris-Acetate, 5 mM magnesium acetate, pH 7.6)
containing 3.0 μM sequencing primer (Table 1) in a 96-
well PSQ HS plate. The primer was annealed to the
ssDNA template by heating the plate at 80 °C for
2 min, then allowing it to cool at room temperature
(21 °C). Pyrosequencing analysis was carried out using
the PSQ96 HS 96A instrument and the SNP Reagent
kit containing dNTPs, enzyme and substrate mixtures
according to manufacturer’s protocols (Pyrosequencing
AB, Uppsala, Sweden).
Statistics
Data were analysed using SPSS 19 (SPSS, Chicago, IL,
USA). Biochemical and clinical data are expressed as
mean ± standard deviation. Continuous data were ana-
lysed with parametric or non-parametric tests according
to the distribution. The chi-square test was used to
compare the categorical data, genotyping and allelic
distributions between patients with neuropathy and
without, genotyping and allelic distributions between
the ethnic groups. Logistic regression analysis was per-
formed with neuropathy as the dependent variable to
analyse the effect of ethnic group, VEGF genotype and
glycated haemoglobin. A value of p ≤ 0.05 was accepted
as significant.
Results
Three hundred and thirteen diabetic patients were in-
cluded in this study, of which forty nine (15.6%) patients
had peripheral neuropathy (Table 2). The prevalence of
peripheral neuropathy was highest in the Caucasian
group (24.6%) compared to the African-Caribbean (14.28%)
and the Indo-Asian ethnic groups (6.7%) (P = 0.04) (Fig. 1).
Patients from the Caucasian origin had more type 1 dia-
betes per comparison to African-Caribbean and Indo-Asian
patients, while the latter had less proportion of smokers per
comparison to the other ethnic groups (Table 3).
The patients with peripheral neuropathy had signifi-
cantly longer duration of diabetes, were older, taller and
were more likely to be men. There were no significant
differences in HbA1c as a measure of glycemic control,
total cholesterol, HDL-cholesterol, and triglyceride levels
between the two groups of patients. The groups had
similar BMI, levels of systolic and diastolic blood pres-
sure, treatment for hypertension and smoking history
(Table 2).
VEGF +405 and −460 polymorphisms and ethnic group
There was a marked disparity in the distribution of the
VEGF +405 genotypes between the Indo-Asian, African-
Caribbean, and Caucasian patients (Table 4). The VEGF
+405 GG was more common in Indo-Asians (67.5%)
compared to African-Caribbean (45.3%) and Caucasian
patients (38.4%) (p ≤ 0.05 and p ≤ 0.005, respectively).
The G allele was more common while the C allele was
less common in the Indo-Asian group per comparison
to the African-Caribbean and Caucasian ethnic groups
(p ≤ 0.02 and p ≤ 0.005, respectively). There were no
Table 1 Primer sequences
VEGF + 405 VEGF-460
Forward primers sequence (5′-3′) GAGAAGTCGAGGAAGAGAGAGACG AATGGAGCGAGCAGCGTCTT
Reverse primer sequence (5′-3′) CCCCAAAAGCAGGTCAC CGTTCCCTCTTTGCTAGGAATAT
Sequencing primers(5′-3′) GTGCGAGCAGCGAAA TGCGTGTGGGGTTGA
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interethnic differences in VEGF −460 genotypes (data
not shown).
VEGF +405 and VEGF −460 gene polymorphisms and
peripheral neuropathy
Genotype frequencies for the +405 C⁄G at the exon 1 of
VEGF gene between patients with peripheral neuropathy
and without peripheral neuropathy are shown in Table 5.
In the analysis of patients with type 2 diabetes only
cohort (n = 253), there was no statistically significant
difference in the VEGF +405 genotype distribution nor
the C and G Allele frequencies (p = 0.76) between the
patients with and without peripheral neuropathy (Table 5).
There was no statistically significant difference be-
tween C and T alleles (p = 0.73) and genotype frequency
of the -460C ⁄T. The analyses also failed to find an associ-
ation between G, C alleles (p = 0.99) or +405C ⁄G VEGF
polymorphism between patients with and without periph-
eral neuropathy (Table 5). In the logistic regression ana-
lysis model with peripheral neuropathy as the dependent
variable we tested the association between the VEGF +405
polymorphism and the quality of diabetes control HbA1c.
The odds ratio (95% confidence interval) was 0.67
(0.47-0.97) for patients of non-Caucasian origin (p = 0.035)
and 1.25 (1.04 – 1.50) for HbA1c (p = 0.015).
Discussion
We found that the distribution of the genetic polymor-
phisms of VEGF +405 and VEGF-460 varied with ethnic
origin, but differences were not found to be associated
with the presence of peripheral neuropathy in this co-
hort of patients with diabetes. Patients of non-Caucasian
origin were 33% less likely to have peripheral neuropathy
compared to Caucasian patients after correcting for
HbA1c.
In recent years, the association of VEGF and diabetic
neuropathy has attracted much attention. Vascular endo-
thelial growth factor is an angiogenic cytokine that can
be induced by hypoxia and increases capillary permeabil-
ity, promote the synthesis of extracellular matrix and
promote the proliferation and hypertrophy of endothelial
cells [18]. However, VEGF can have deleterious effects
on the basement membrane of vessels, increasing endo-
neurial vascular permeability, leading to nerve fibre ische-
mia and hypoxia, and thus contributing to the occurrence
of neuropathy [19, 20].
In animal models of diabetes and neuropathy, increased
VEGF staining has been reported in neuronal cell bodies
Table 2 Demographic and clinical characteristics of diabetic







Age (years) 67.48 ± 8.18** 60.60 ± 11.29
Diabetes(Type1/Type2)% 8.6/91.4 12.9/87.1
Duration of diabetes (years) 22.16 ± 9.45** 15.73 ± 8.01
Gender (male/female)% 65.6/34.4* 46.6/52.9




Systolic blood pressure (mmHg) 143.04 ± 20.77 144.16 ± 21.68
Diastolic blood pressure (mmHg) 77.36 ± 10.14 81.14 ± 11.24
Hypertensive (%) 65.3 65.1
Total Cholesterol (mmol/L) 4.5 ± 1.4 4.67 ± 1.19
HDL-Cholesterol (mmol/L) 1.19 ± 0.29 1.43 ± 0.41
Triglycerides(mmol/L) 2.33 ± 1.99 1.99 ± 1.4
BMI (Kg/m2) 31.98 ± 4.86 31.03 ± 6.57




Data expressed as mean ± SD
*p ≤ 0.05
**p ≤ 0.001
Fig. 1 Prevalence of peripheral neuropathy in patients with diabetes from Caucasian, African Caribbean and Indo-Asian origin)
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in dorsal root ganglia, axons and in Schwann cells of per-
ipheral nerves, also, higher circulating levels of the cyto-
kine have been reported in comparison to healthy animals
[21, 22]. Treatment with plasmid DNA encoding for
VEGF was shown to improve sensory behavioural features
and sciatic nerve blood flow [20]. Clinical studies using
the intramuscular plasmid VEGF gene transfer have been
shown to improve neuropathic symptoms in patients with
diabetes [23].
The VEGF +405 and VEGF −460 gene polymorphisms
were not shown to be associated with peripheral neur-
opathy in our patients. However whether VEGF accounts
for the differential vulnerability to neuropathy amongst
patients of different ethnic background remains to be de-
termined. In our study, the Indo-Asian ethnic group with
the lowest prevalence of neuropathy had the highest fre-
quency of the +405 GG VEGF genotype, which has been
shown to be associated with raised plasma VEGF levels
[11]. It is reported that patients with type 2 diabetes of
Indo-Asian and African-Caribbean origin are less likely to
develop neuropathy and foot ulceration compared with
those of Caucasian origin [7–10]. In our cohort though we
found a near 3-fold greater prevalence of clinically evident
peripheral neuropathy in the Caucasian patient group
compared with the non-Caucasian group. The relatively
high prevalence of peripheral neuropathy in this cohort is
in part due to these patients being attendees of a second-
ary care centre and there are differences in methodologies
reported in different centres for case finding. In contrast
to other studies we used the 10 g monofilament in con-
secutive patients, whereas other studies used the neu-
rothesiometer and biothesiometer in selected patients
[8, 10, 24]. Patients of non-Caucasian background are
generally poorly represented in research studies in the
UK and the lack of standardisation in the methodologies
to diagnose neuropathy may have affected the reported
Table 3 Demographic and clinical characteristics of Indo-Asian, African-Caribbean and Caucasian patients
DEMOGRAPHIC/CLINICAL parameters Indo-Asian African-Caribbean Caucasian
Age (years) 59.47 ± 10.62 56.49 ± 12.06 56.90 ± 15.78
Diabetes(Type1/Type2)% 6.06/93.94 3.08/96.92 21.47/78.53*
Duration of diabetes (years) 17.34 ± 7.26 15.42 ± 8.65 16.66 ± 10.27
Gender (male/female)% 61.8/38.2 43.8/56.2 57.5/42.5
Smoking history (yes/No) % 51.9/48.1 73.7/26.7 76.1 /23.9*
Systolic blood pressure (mmHg) 147.82 ± 24.42 145.62 ± 21.33 140.33 ± 23.02
Diastolic blood pressure(mmHg) 82.33 ± 10.70 83.35 ± 12.62 79.11 ± 11.09
Total Cholesterol (mmol/L) 4.73 ± 0.91 4.59 ± 1.18 4.98 ± 0.92
HDL-Cholesterol (mmol/L) 1.3 ± 0.64 1.42 ± 0.36 1.35 ± 0.36
Triglycerides (mmol/L) 2.22 ± 1.12 1.67 ± 0.94 2.140 ± 1.13
Height (m) 1.62 ± 0.10 1.65 ± 0.09 1.66 ± 0.11
BMI (Kg/m2) 27.37 ± 4.57 30.73 ± 6.43 31.66 ± 7.37
HbA1c % 7.5 ± 1.24 8.33 ± 1.78 7.9 ± 1.62
Data expressed as mean ± SD
*p ≤ 0.005
Table 4 VEGF +405 genotypes in type 2 diabetes patients from
Indo-Asian, African Caribbean and Caucasian origin
VEGF + 405 genotypes Indo-Asian African-Caribbean Caucasian
CG (%) 13 (32.5)a, b 36 (48.0) 79 (57.25)
CC (%) 0 (0) 5 (6.7) 6 (4.35)
GG (%) 27 (67.5)a, b 34 (45.3) 53 (38.4)
C (%) 13 (16.25)c, d 46 (30.67) 91 (32.97)
G (%) 67 (83.75)c, d 104 (69.33) 185 (67.03)
aCompared to African Caribbean (χ2 = 6.5541, p ≤ 0.05)
bCompared to Caucasian (χ2 = 11.2541, p ≤ 0.005)
cCompared to African Caribbean (χ2 = 5.6858, p ≤ 0.02)
dCompared to Caucasian (χ2 = 8.3857, p ≤ 0.005)
Table 5 Genotype and Allele frequencies of the VEGF + 405
gene polymorphisms in patients with and without neuropathy
VEGF + 405 Polymorphism With Neuropathy Without
neuropathy
1) Whole population Genotypes N = 35 N = 264
CG (%) 18 (51.4) 134 (50.8)
GG (%) 16 (45.7) 119 (45.1)
CC (%) 1 (2.9) 11 (4.2)
C (%) 21 (29.58) 156 (29.55)
G (%) 50 (70.42) 372 (70.45)
2) Type 2 diabetes Genotypes N = 32 N = 221
CC (%) 1 (3.1) 10 (4.5)
CG (%) 18 (56.3) 110 (49.8)
GG (%) 13 (40.6) 101 (45.6)
C (%) 20 (31.25) 130 (29.41)
G (%) 44 (68.75) 312 (70.59)
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prevalence [25]. However, if the prevalence of neuropathy
is similar between these ethnic groups there would have
been clear ethnic similarities in the rates of penetrative ul-
ceration and limb amputation. Insensitivity to the 10 g
monofilament increases the 2 year risk of ulceration nearly
3-fold [26]. However, the rates of lower limb amputation
amongst patients with diabetes of Indo-Asian compared
to Caucasian origin are significantly lower in the UK [27].
In this cross-sectional study, the VEGF +405 poly-
morphism distribution was similar between patients of
African-Caribbean and Caucasian origin and the fre-
quencies of the G and C alleles were similar between the
ethnic groups. These findings are in line with the only
two other studies that looked at VEGF +405 polymorphism
and ethnicity [28, 29]. Moreover, the frequencies found for
the VEGF +405G Allele in this cohort of patients of Cauca-
sian and African-Caribbean origin (67% and 69%, respect-
ively) are similar to those reported in American whites and
black individuals without diabetes and vascular disease [28]
and in white and black Brazilians [29]. These findings
suggest that VEGF +405 genotype distribution and al-
lele frequencies are similar across ethnic groups when
comparing Caucasian and African-Caribbean cohorts in
the presence or absence of diabetes.
Our study found that VEGF +405 GG genotype was
more common in patients of Indo-Asian origin in com-
parison to African-Caribbean and Caucasian patients. In
addition, the frequency of the VEGF +405G allele was
higher in the Indo-Asian patients (83.75%) per compari-
son to African-Caribbean and Caucasian patients (67%
and 69%, respectively). Previous research demonstrated
that Lipopolysaccharide stimulated peripheral blood
mononuclear cell VEGF protein production was highest
among individuals who were VEGF +405GG [11] and
high expression of VEGF was protective for ischemic
neuronal damage [30, 31]. It can be postulated that
VEGF +405GG has a protective role against neuropathy
and may explain why patients of Indo-Asian origin,
should they develop ulceration may have better rates of
healing, and therefore lower rates of amputation [26].
Furthermore, the VEGF −460 polymorphism, which has
not been correlated to plasma VEGF concentration [11]
was not different between the ethnic groups.
Although, this study did not measure serum VEGF
concentration, elevated serum VEGF levels have been
reported in healthy subjects with the VEGF +405CC
genotype and not the VEGF +405 GG [12]. Lambrechts
and colleagues [32] demonstrated that production of
large-VEGF isoform with the VEGF +405G allele in cell
extracts was 20% lower in comparison to VEGF +405C
allele. It has also been shown that haplotypes of VEGF
-2578A/−1154A/+405G and -2578A/−1154G/+405G in
the VEGF promoter/leader lowered circulating VEGF levels
in vivo and reduced VEGF gene transcription [32]. Similar
results were reported in cultured human myoblasts that
analysed the effects of the VEGF −2578/−1154/+405
promoter region haplotype on VEGF gene expression
[28]. Moreover, ethnic differences in VEGF haplotypes
-2578C/−1154G/+405G were reported to be more com-
mon in Black than White Brazilian individuals even
though these groups had similar profile in VEGF + 405
genotype [29]. Collectively, these studies and our study
findings suggest that ethnic differences in various VEGF
polymorphisms exist, and the possible association between
these VEGF genotypes including VEGF +405 might influ-
ence circulating VEGF concentrations.
The prevalence of peripheral neuropathy in this real-
world selected cohort is in agreement with previous stud-
ies with regards to the vulnerability of Caucasian patients
to peripheral neuropathy in comparison to other ethnic
groups [7, 8, 24]. Glycaemic control is the major factor in
the development of diabetic neuropathy [5, 24, 33]. In the
current study, there were no differences in HbA1c in
the patients with, compared to those without neuropathy.
Furthermore, in correcting for glycaemic control non-
Caucasian ethnic group appears to be a protective factor
for the development of neuropathy.
A number of studies in small groups of patients have
identified an association between diabetic neuropathy
and VEGF gene polymorphisms, but not the propensity
to develop diabetic neuropathy or the healing process.
The VEGF gene SNP at −7*C/T was associated with dia-
betic neuropathy in type 1 diabetic patients of British
Caucasian origin [34]. Another VEGF polymorphism that
was associated with diabetic neuropathy is VEGF 936 C/T
in type 2 diabetic Chinese patients [35]. The latest VEGF
polymorphism that was reported to be associated with
neuropathy is the Insertion/deletion VEGF gene that was
studied in type 2 diabetes population [36].
Conclusions
The present study is the first to examine the distribution
of VEGF +405 and VEGF −460 genotypes in African-
Caribbean, Indo-Asian and Caucasian patients with
diabetes and the association of these genotypes with
peripheral neuropathy. Although there was a difference in
the VEGF + 405 polymorphism and the frequencies of G
and C alleles between the ethnic groups, this study did not
find any association with diabetic neuropathy regardless of
diabetes type or ethnic origin. The results may suggest
that neither VEGF +405 nor VEGF −460 polymorphisms
are involved with diabetic peripheral neuropathy. However
the complexity of VEGF gene expression and the small
sample size of the enrolled population limits our conclu-
sions. These findings support a hypothesis that the VEGF
+405 genotype may confer protection from developing
peripheral neuropathy and therefore the risk of developing
foot ulceration and lower limb amputation in patients of
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non-Caucasian origin in the UK. This study results re-
iterate the need for further research into the possible
relationship between VEGF genotypes, circulating VEGF
concentrations and differential vulnerability to peripheral
neuropathy in patients with diabetes of different ethnic
backgrounds.
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